Clancy M, Graepler A, Breese P, Price C, Burman W. The widespread emergence of methicillin resistance in community-acquired Staphylococcus aureus Infections in Denver. South Med J, 2005; 98: 1069-75.
Gardner E, Burman W, Maravi M, Davidson A. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. JAIDS, 2005; 40: 294-300.
Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, LaHart C, Weis S, King B, Mangura B, Weiner M, El-Sadr W. Acquired rifamycin-resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med, 2006; 173: 350-6.
Jenkins T, Gardner E, Thrun M, Cohn D, Burman W. Risk-based HIV testing fails to detect the majority of HIV-infected persons in medical care settings. Sex Trans Dis, 2006; 33:329-333.
Gardner EM, Burman WJ, Maravi ME. Davidson AJ. Durability of adherence to antiretroviral therapy on initial and subsequent regimens. AIDS Patient Care STDs, 2006; 20: 628-36.
Burman W, Goldberg S, Johnson J, Muzanye G, Engle M, Mosher A, Choudri S, Daley CL, Munsiff S, Zhao Z, Vernon A, Chaisson R, and the Tuberculosis Trials Consortium. Moxifloxacin versus ethambutol in the first two months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med, 2006; 174:331-8.
The SMART Study Group (member of the writing group). CD4-guided antiretroviral treatment interruption. N Engl J Med, 2006; 355(22): 2283-96.
Weiner M, Burman W, Luo CC, Peloquin CA, Emgle M, Goldberg S, Agarwal V, Vernon A. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother, in press.
Burman W. Issues in the treatment of HIV-related tuberculosis. Clin Chest Med, 2005; 26: 283-94.
Mitnick C, Castro K, Harrington M, Sacks L, Burman W. Randomized trials to optimize treatment of MDR-TB: the time for action is now. PLOS Medicine, in press.